Skip to main content

Featured

CUSMA Renewal Deadline Passes: What It Means for Your Wallet

  July 8, 2026 July 1 came and went without a full renewal of the Canada-United States-Mexico Agreement (CUSMA). Instead of locking in another 16-year term, the United States chose not to extend the deal in its current form, which means the trade pact now shifts into an annual review process for the next decade. Here's what that actually means for your money. What just happened All three countries had until July 1 to say whether they wanted to renew CUSMA. Because Washington opted against a full renewal, the agreement now gets reviewed annually rather than being locked in for over a decade. Canada's Trade Minister Dominic LeBlanc confirmed the three countries agreed to keep talking, with Canada specifically pushing to address sectoral tariffs on steel, aluminum, autos, and lumber. Any of the three countries can still walk away entirely with six months' notice. The good news: most trade stays tariff-free For now, the status quo holds. The bulk of Canadian exports to the U.S....
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment